Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Arm A1 vs Arm B: Overall Survival (OS)

OS is defined as the time from the date of randomization to the date of death of any cause.

Time frame: Up to 10 Years

Arm A1 vs Arm B: Rate of Minimal Residual Disease (MRD) Negativity Rate

MRD negativity rate, defined as the absence of tumor specific molecules in whole blood and/or bone marrow in participants with follicular lymphoma (FL) MRD at baseline.

Time frame: Up to 10 Years

Arm A1 vs Arm B: Change from Baseline in Physical Functioning (PF) According to European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer (EORTC QLQ-C30)

The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.

Time frame: 21 Weeks

Arm A1 vs Arm A2: Percentage of Participants who Achieve CR30

CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.

Time frame: Up to 30 Months

Arm A1 vs Arm C: Percentage of Participants who Achieve CR30

CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.

Time frame: Up to 30 Months

Arm A1 vs Arm A2: Number of Participants with PFS

PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Number of Participants with PFS

PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Rate of MRD Negativity

MRD negativity, defined as the absence of tumor specific molecules in whole blood and/or bone marrow in participants with FL MRD at baseline.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Rate of MRD Negativity

MRD negativity, defined as the absence of tumor specific molecules in whole blood and/or bone marrow in participants with FL MRD at baseline.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Change from Baseline in PF According to EORTC QLQ-C30

The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Change from Baseline in PF According to EORTC QLQ-C30

The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: OS

OS is defined as the time from the date of randomization to the date of death of any cause.

Time frame: Up to 10 Years

Arm A1 vs Arm C: OS

OS is defined as the time from the date of randomization to the date of death of any cause.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Percentage of Participants who Achieve CR30

CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.

Time frame: Up to 30 Months

Arm A1 vs Arm B: Percentage of Participants who Achieve CR30

CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.

Time frame: Up to 30 Months

Arm A1 vs Arm C: Percentage of Participants who Achieve CR30

CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.

Time frame: Up to 30 Months

Arm A1 vs Arm A2: Number of Participants with PFS

PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.

Time frame: Up to 10 Years

Arm A1 vs Arm B: Number of Participants with PFS

PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Number of Participants with PFS

PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Percentage of Participants with Change in CR Rate per IRC

CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Percentage of Participants with Change in CR Rate per Investigator

CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.

Time frame: Up to 10 Years

Arm A1 vs Arm B: Percentage of Participants with Change in CR Rate per IRC

CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.

Time frame: Up to 10 Years

Arm A1 vs Arm B: Percentage of Participants with Change in CR Rate per Investigator

CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Percentage of Participants with Change in CR Rate per IRC

CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Percentage of Participants with Change in CR Rate per Investigator

CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Number of Participants with Best Overall Response (BOR) per per Investigator

BOR is defined as the percentage of participants who achieve CR or partial response (PR) determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Number of Participants with BOR per IRC

BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by IRC, or death from any cause.

Time frame: Up to 10 Years

Arm A1 vs Arm B: Number of Participants with BOR per Investigator

BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.

Time frame: Up to 10 Years

Arm A1 vs Arm B: Number of Participants with BOR per IRC

BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by IRC, or death from any cause.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Number of Participants with BOR per Investigator

BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Number of Participants with BOR per IRC

BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by IRC, or death from any cause.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Number of Participants with Event-free Survival (EFS) per IRC

EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Number of Participants with EFS per Investigator

EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.

Time frame: Up to 10 Years

Arm A1 vs Arm B: Number of Participants with EFS per IRC

EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.

Time frame: Up to 10 Years

Arm A1 vs Arm B: Number of Participants with EFS per Investigator

EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Number of Participants with EFS per IRC

EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Number of Participants with EFS per Investigator

EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Duration of Response (DOR) per IRC

DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by IRC.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: DOR per Investigator

DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by investigator.

Time frame: Up to 10 Years

Arm A1 vs Arm B: DOR per IRC

DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by IRC.

Time frame: Up to 10 Years

Arm A1 vs Arm B: DOR per Investigator

DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by investigator.

Time frame: Up to 10 Years

Arm A1 vs Arm C: DOR per IRC

DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by IRC.

Time frame: Up to 10 Years

Arm A1 vs Arm C: DOR per Investigator

DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by investigator.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Duration of Complete Response (DOCR) per IRC

DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by IRC.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: DOCR per Investigator

DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by investigator.

Time frame: Up to 10 Years

Arm A1 vs Arm B: DOCR per IRC

DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by IRC.

Time frame: Up to 10 Years

Arm A1 vs Arm B: DOCR per Investigator

DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by investigator.

Time frame: Up to 10 Years

Arm A1 vs Arm C: DOCR per IRC

DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by IRC.

Time frame: Up to 10 Years

Arm A1 vs Arm C: DOCR per Investigator

DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by investigator.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Time to Next Anti-lymphoma Therapy (TTNT) per Investigator

TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: TTNT per IRC

TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: TTNT per Investigator

TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.

Time frame: Up to 10 Years

Arm A1 vs Arm B: TTNT per IRC

TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.

Time frame: Up to 10 Years

Arm A1 vs Arm B: TTNT per Investigator

TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.

Time frame: Up to 10 Years

Arm A1 vs Arm C: TTNT per IRC

TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.

Time frame: Up to 10 Years

Arm A1 vs Arm C: TTNT per Investigator

TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Time to Progression per IRC

Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by IRC.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Time to Progression per Investigator

Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by investigator.

Time frame: Up to 10 Years

Arm A1 vs Arm B: Time to Progression per IRC

Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by IRC.

Time frame: Up to 10 Years

Arm A1 vs Arm B: Time to Progression per Investigator

Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by investigator.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Time to Progression per IRC

Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by IRC.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Time to Progression per Investigator

Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by investigator.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Number of Participants with Progression-free Survival After Subsequent Anti-Lymphoma Therapy (PFS2)

PFS2 is defined as the time after subsequent anti-lymphoma therapy to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.

Time frame: Up to 10 Years

Arm A1 vs Arm B: Number of Participants with PFS2

PFS2 is defined as the time after subsequent anti-lymphoma therapy to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Number of Participants with PFS2

PFS2 is defined as the time after subsequent anti-lymphoma therapy to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Change in Tolerability as Measured by Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE)

The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in participants in cancer clinical trials. PRO-CTCAE items evaluate common symptoms from study treatment on their frequency, severity, interference, amount, presence/absence.

Time frame: Up to 10 Years

Arm A1 vs Arm B: Change in Tolerability as Measured by PRO-CTCAE

The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in participants in cancer clinical trials. PRO-CTCAE items evaluate common symptoms from study treatment on their frequency, severity, interference, amount, presence/absence.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Change in Tolerability as Measured by PRO-CTCAE

The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in participants in cancer clinical trials. PRO-CTCAE items evaluate common symptoms from study treatment on their frequency, severity, interference, amount, presence/absence.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Change in Tolerability as Measured by The Functional Assessment of Cancer Therapy - General (FACT-G) Item GP5

The functional assessment of cancer therapy singly item - GP5 (FACT-GP5) is a single question asking if participant is bothered by side effects of treatment.

Time frame: Up to 10 Years

Arm A1 vs Arm B: Change in Tolerability as Measured by FACT-G Item GP5

The FACT-GP5 is a single question asking if participant is bothered by side effects of treatment.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Change in Tolerability as Measured by FACT-GG Item GP5

The FACT-GP5 is a single question asking if participant is bothered by side effects of treatment.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Change in Symptoms as Measured by The Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym)

The objective of the FACT-Lym patient reported outcome (PRO) is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.

Time frame: Up to 10 Years

Arm A1 vs Arm B: Change in Symptoms as Measured by FACT-Lym

The objective of the FACT-Lym patient reported outcome (PRO) is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Change in Symptoms as Measured by FACT-Lym

The objective of the FACT-Lym patient reported outcome (PRO) is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Change in Quality of Life (QoL) as Measured by FACT-Lym

The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.

Time frame: Up to 10 Years

Arm A1 vs Arm B: Change in QoL as Measured by FACT-Lym

The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Change in QoL as Measured by FACT-Lym

The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Time-to-first PRO deterioration (TTD) in well-being using the lymphoma subscale (LymS) of FACT-Lym

The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.

Time frame: Up to 10 Years

Arm A1 vs Arm B: TTD in well-being using LymS of FACT-Lym

The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.

Time frame: Up to 10 Years

Arm A1 vs Arm C: TTD in well-being using LymS of FACT-Lym

The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Change in QoL as Measured by 5-Level European Quality of Life (EuroQol)-5-dimension [EQ-5D-5L]

The EQ-5D-5L is a standardized, non-disease specific instrument used to measure health-related quality of life. The EQ-5D-5L assesses general health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The scores for the 5 dimensions are used to compute a single utility index score ranging from 0 to 1 representing the general health status of the individual, with higher scores indicating better health state.

Time frame: Up to 10 Years

Arm A1 vs Arm B: Change in QoL as Measured by EQ-5D-5L

The EQ-5D-5L is a standardized, non-disease specific instrument used to measure health-related quality of life. The EQ-5D-5L assesses general health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The scores for the 5 dimensions are used to compute a single utility index score ranging from 0 to 1 representing the general health status of the individual, with higher scores indicating better health state.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Change in QoL as Measured by EQ-5D-5L

The EQ-5D-5L is a standardized, non-disease specific instrument used to measure health-related quality of life. The EQ-5D-5L assesses general health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The scores for the 5 dimensions are used to compute a single utility index score ranging from 0 to 1 representing the general health status of the individual, with higher scores indicating better health state.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: TTD in PF using the QLQ-C30 Physical Functioning Scale

The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.

Time frame: Up to 10 Years

Arm A1 vs Arm B: TTD in PF using the QLQ-C30 Physical Functioning Scale

The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.

Time frame: Up to 10 Years

Arm A1 vs Arm C: TTD in PF using the QLQ-C30 Physical Functioning Scale

The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Change from baseline in the remaining items and domains of the EORTC QLQ-C30

The EORTC QLQ-C30: A 30 items questionnaire to assess the quality of life of cancer patients on physical, emotional, cognitive, and social functions and symptoms. with a higher score indication worse quality of life.

Time frame: Up to 10 Years

Arm A1 vs Arm B: Change from baseline in the remaining items and domains of the EORTC QLQ-C30

The EORTC QLQ-C30: A 30 items questionnaire to assess the quality of life of cancer patients on physical, emotional, cognitive, and social functions and symptoms. with a higher score indication worse quality of life.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Change from baseline in the remaining items and domains of the EORTC QLQ-C30

The EORTC QLQ-C30: A 30 items questionnaire to assess the quality of life of cancer patients on physical, emotional, cognitive, and social functions and symptoms. with a higher score indication worse quality of life.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Change in Patient Global Impression of Change (PGIC) for General Lymphoma Symptoms

The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. The PGIC is a 7-point scale depicting a participant's rating of overall improvement since start of treatment. Participants rate their change as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Change in PGIC for General Lymphoma Symptoms

The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. The PGIC is a 7-point scale depicting a participant's rating of overall improvement since start of treatment. Participants rate their change as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.

Time frame: Up to 10 Years

Arm A1 vs Arm A2: Change in Patient Global Impression of Severity (PGIS) for General Lymphoma Symptoms

The self-report measure PGIS reflects a participant's belief about their lymphoma symptoms over the past 7 days. The PGIS is a 5-point scale depicting a participant's rating of overall severity.

Time frame: Up to 10 Years

Arm A1 vs Arm B: Change in PGIS for General Lymphoma Symptoms

The self-report measure PGIS reflects a participant's belief about their lymphoma symptoms over the past 7 days. The PGIS is a 5-point scale depicting a participant's rating of overall severity.

Time frame: Up to 10 Years

Arm A1 vs Arm C: Change in PGIS for General Lymphoma Symptoms

The self-report measure PGIS reflects a participant's belief about their lymphoma symptoms over the past 7 days. The PGIS is a 5-point scale depicting a participant's rating of overall severity.

Time frame: Up to 10 Years